You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,958,337


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,958,337
Title: Crystalline antifungal polymorph
Abstract:The crystalline polymorph Form I of (-)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-tri azol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro -2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I ##STR1## pharmaceutical compositions containing such a polymorph and methods of using such a polymorph to treat fungal infections in mammals are disclosed.
Inventor(s): Andrews; David R. (Maplewood, NJ), Leong; William (Westfield, NJ), Sudhakar; Anantha (East Brunswisk, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/786,886
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,958,337
Patent Claims: 1. A crystalline polymorph Form I of the compound represented by the formula I ##STR4##

and characterized by at least one of the following properties: a melting point range of about 164 to about 165.degree. C. wherein the melting point range is determined using USP Class Ia procedure; a specific rotation equal to [a].sup.25.sub.D =-29.4.degree. wherein the specific rotation is determined using a concentration of 10 mg/ml in methanol; an X-ray powder diffraction pattern substantially similar to that presented in FIG. 1; a differential scanning calorimetry thermogram substantially similar to that presented in FIG. 7; or the proton NMR spectrum substantially similar to that presented in FIG. 10.

2. A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form I of claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form I of claim 1.

4. A crystalline polymorph Form III of the compound represented by the formula I ##STR5##

and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 28.69, 14.45, 10.59, 7.27, 6.59, 4.14, 3.58, and 3.53 +/-0.04.

5. The crystalline polymorph Form III of claim 4 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in FIG. 3.

6. A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form III of claim 4 and a pharmaceutically acceptable carrier.

7. A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form III of claim 4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.